Hurst R, Brewer D, Gihawi A, Wain J, Cooper C
J Med Microbiol. 2024; 73(3).
PMID: 38535967
PMC: 10995961.
DOI: 10.1099/jmm.0.001817.
Uehara M, Domoto T, Takenaka S, Takeuchi O, Shimasaki T, Miyashita T
Cancer Drug Resist. 2024; 7:4.
PMID: 38318525
PMC: 10838383.
DOI: 10.20517/cdr.2023.84.
Park J, Kang S, Kwon W, Jeong I, Kim T, Yu S
Sci Rep. 2023; 13(1):22648.
PMID: 38114573
PMC: 10730520.
DOI: 10.1038/s41598-023-49646-5.
Martinez-Jimenez F, Movasati A, Brunner S, Nguyen L, Priestley P, Cuppen E
Nature. 2023; 618(7964):333-341.
PMID: 37165194
PMC: 10247378.
DOI: 10.1038/s41586-023-06054-z.
Qiu Y, Xu B, Feng J, Wang C, Chen Y, He Y
Cancer Gene Ther. 2023; 30(7):997-1006.
PMID: 36932195
DOI: 10.1038/s41417-023-00606-1.
Deep learning-based multi-drug synergy prediction model for individually tailored anti-cancer therapies.
She S, Chen H, Ji W, Sun M, Cheng J, Rui M
Front Pharmacol. 2023; 13:1032875.
PMID: 36588694
PMC: 9797718.
DOI: 10.3389/fphar.2022.1032875.
Systematic Pan-Cancer Analysis Identifies CDK1 as an Immunological and Prognostic Biomarker.
Yang Y, Liu Q, Guo X, Yuan Q, Nian S, Kang P
J Oncol. 2022; 2022:8115474.
PMID: 36090896
PMC: 9452984.
DOI: 10.1155/2022/8115474.
A Network-Guided Approach to Discover Phytochemical-Based Anticancer Therapy: Targeting MARK4 for Hepatocellular Carcinoma.
Ahmed S, Mobashir M, Al-Keridis L, Alshammari N, Adnan M, Abid M
Front Oncol. 2022; 12:914032.
PMID: 35936719
PMC: 9355243.
DOI: 10.3389/fonc.2022.914032.
Identification of Extracellular Matrix Signatures as Novel Potential Prognostic Biomarkers in Lung Adenocarcinoma.
Zeng Z, Zuo Y, Jin Y, Peng Y, Zhu X
Front Genet. 2022; 13:872380.
PMID: 35711936
PMC: 9197387.
DOI: 10.3389/fgene.2022.872380.
Towards targeting of shared mechanisms of cancer metastasis and therapy resistance.
Weiss F, Lauffenburger D, Friedl P
Nat Rev Cancer. 2022; 22(3):157-173.
PMID: 35013601
PMC: 10399972.
DOI: 10.1038/s41568-021-00427-0.
Quantitative analysis of tumour spheroid structure.
Browning A, Sharp J, Murphy R, Gunasingh G, Lawson B, Burrage K
Elife. 2021; 10.
PMID: 34842141
PMC: 8741212.
DOI: 10.7554/eLife.73020.
Lamellipodin-RICTOR Signaling Mediates Glioblastoma Cell Invasion and Radiosensitivity Downstream of EGFR.
Moritz S, Krause M, Schlatter J, Cordes N, Vehlow A
Cancers (Basel). 2021; 13(21).
PMID: 34771501
PMC: 8582497.
DOI: 10.3390/cancers13215337.
Identification of a Putative Enhancer RNA for EGFR in Hyper-Accessible Regions in Esophageal Squamous Cell Carcinoma Cells by Analysis of Chromatin Accessibility Landscapes.
Choi S, Sathe A, Mathe E, Xing C, Pan Z
Front Oncol. 2021; 11:724687.
PMID: 34722266
PMC: 8554337.
DOI: 10.3389/fonc.2021.724687.
Naringenin Sensitizes Resistant C6 Glioma Cells with a Repressive Impact on the Migrating Ability.
J J, Vanisree A
Ann Neurosci. 2021; 27(3-4):114-123.
PMID: 34556949
PMC: 8455008.
DOI: 10.1177/0972753120950057.
GBP5 drives malignancy of glioblastoma via the Src/ERK1/2/MMP3 pathway.
Yu X, Jin J, Zheng Y, Zhu H, Xu H, Ma J
Cell Death Dis. 2021; 12(2):203.
PMID: 33608513
PMC: 7896088.
DOI: 10.1038/s41419-021-03492-3.
Hold on or Cut? Integrin- and MMP-Mediated Cell-Matrix Interactions in the Tumor Microenvironment.
Niland S, Eble J
Int J Mol Sci. 2020; 22(1).
PMID: 33379400
PMC: 7794804.
DOI: 10.3390/ijms22010238.
Resistance Mechanisms of Anti-angiogenic Therapy and Exosomes-Mediated Revascularization in Cancer.
Zeng Y, Fu B
Front Cell Dev Biol. 2020; 8:610661.
PMID: 33363174
PMC: 7755714.
DOI: 10.3389/fcell.2020.610661.
Adjuvant effect of low-carbohydrate diet on outcomes of patients with recurrent glioblastoma under intranasal perillyl alcohol therapy.
Santos J, Faria G, Cruz W, Fontes C, Schonthal A, Quirico-Santos T
Surg Neurol Int. 2020; 11:389.
PMID: 33282452
PMC: 7710475.
DOI: 10.25259/SNI_445_2020.
Glycogen synthase kinase-3β participates in acquired resistance to gemcitabine in pancreatic cancer.
Uehara M, Domoto T, Takenaka S, Bolidong D, Takeuchi O, Miyashita T
Cancer Sci. 2020; 111(12):4405-4416.
PMID: 32986894
PMC: 7734171.
DOI: 10.1111/cas.14668.
Intrinsic and Extrinsic Modulators of the Epithelial to Mesenchymal Transition: Driving the Fate of Tumor Microenvironment.
DAngelo E, Lindoso R, Sensi F, Pucciarelli S, Bussolati B, Agostini M
Front Oncol. 2020; 10:1122.
PMID: 32793478
PMC: 7393251.
DOI: 10.3389/fonc.2020.01122.